Preliminary Remediation Begins On Restarting Formula Production At Abbott Nutrition Plant
Executive Summary
Decree imposes steps Abbott must complete before it can begin preparing to restart production, including hiring independent consultant to determine whether facility is compliant with FDA manufacturing and labeling regulations.
You may also be interested in...
Weighing Shortage Risk, FDA Clears Releasing Metabolic Formulas Made At Abbott’s Closed Plant
With Michigan facility closed as cause of bacterial contamination is investigated, FDA announces “has no objection” to Abbott releasing specialty and metabolic formulas “to individuals needing urgent, life-sustaining supplies” on a case-by-case basis.
Recall Sours Abbott’s Infant Formula Results; COVID-19 Test Sales Expected To Cool
Worldwide nutrition sales, adult as well as infant products, during Q1 dropped reported 7% to $1.89bn. US sales were $59m, well below $288m in prior-year period.
Jurors' Answers In FTC Complaint Against Prevagen Might Form A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.